In the bio-tech sector, focus has been homed in on the actions of
Kellanova (NYSE:K).
Corient Private Wealth LLC reduced its holdings in Kellanova, while
Franklin Resources Inc and
SageView Advisory Group LLC have increased their investment. Despite the company missing its earnings estimates, the stock rose notably following its Q1 report, which details a sales beat from its previous quarter.
Kellogg W. K. Foundation Trust, a major holder, sold a slew of shares, yet Kellanova remains attractive to other stakeholders.
Wells Fargo & Company MN and
Intech Investment Management LLC have boosted their stakes. Meanwhile, forecasts suggest promising growth for Kellanova. The stock experienced fluctuation, rising on some days, and falling at other times. It has been highlighted that Kellanova is dependent on international revenue. Interestingly, the former Kellogg entity seems to have shown underlying earnings growth. However, higher prices seem to be hampering sales.
Tom's Capital notably took a significant stake. Kellanova, concluded its business separation. However, questions regarding CEO compensation have been raised.
Kellanova Stocks K News Analytics from Tue, 25 Jul 2023 07:00:00 GMT to Thu, 30 May 2024 10:51:52 GMT -
Rating 2
- Innovation -3
- Information 7
- Rumor -1
